AI Article Synopsis
- Hepatocellular carcinoma (HCC) is a common and deadly cancer, and long noncoding RNAs like HOTAIR may help diagnose it.
- In a study, researchers measured serum HOTAIR levels in patients with hepatitis, liver cirrhosis, and HCC, finding higher levels in HCC patients.
- The results suggest that HOTAIR could be an effective diagnostic marker for HCC, especially when used alongside other clinical indicators like HBeAg and AFP, improving overall diagnostic accuracy.
Article Abstract
Background/aims: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and the third leading cause of cancer-related mortality. Extensive literature suggests that long noncoding RNAs play a role in the progression of HCC and hold potential as diagnostic biomarkers for this disease.
Materials And Methods: We examined the serum levels of HOX antisense intergenic RNA (HOTAIR) in 49 hepatitis patients, 31 liver cirrhosis (LC), and 37 HCC patients using quantitative real-time polymerase chain reaction. Correlations between serum HOTAIR levels and clinical data were evaluated in HCC patients. The receiver operating characteristic curve was utilized to analyze the diagnostic potency of HOTAIR.
Results: The HOTAIR levels in serum were significantly higher in HCC patients compared to those with hepatitis (P = .003) and LC patients (P = .048). There was a significant association between the serum levels of HOTAIR and positivity of hepatitis B e antigen (HBeAg) (P = .039) as well as portal vein tumor thrombus (P = .040) in HCC patients. The area under the curve (AUC) for HOTAIR for distinguishing HCC from hepatitis and LC was 0.697. The combined AUC for HOTAIR, HBeAg, and alpha-fetoprotein (AFP) was 0.777.
Conclusion: Serum HOTAIR functions as a potential diagnostic marker for hepatitis B virus-related HCC. Combining HOTAIR with clinical data and AFP can reinforce the diagnostic precision on HCC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181209 | PMC |
| http://dx.doi.org/10.5152/tjg.2024.23314 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Refining MR-guided thermal ablation for HCC within the Milan criteria: a decade of clinical outcomes and predictive modeling at a single institution.
BMC Cancer
January 2025
Department of Interventional Radiology, First Affiliated Hospital of Fujian Medical University, Fuzhou, 350000, China.
Background: The appropriateness of ablation for liver cancer patients meeting the Milan criteria remains controversial.
Purpose: This study aims to evaluate the long-term outcomes of MR-guided thermal ablation for HCC patients meeting the Milan criteria and develop a nomogram for predicting survival rates.
Methods: A retrospective analysis was conducted from January 2009 to December 2021 at a single institution.
The spectrum and outcome of metastatic hepatocellular carcinoma in a South African patient cohort.
HPB (Oxford)
January 2025
Surgical Gastroenterology Unit, Division of General Surgery, University of Cape Town Faculty of Health Sciences and Groote Schuur Hospital, Cape Town, South Africa. Electronic address:
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death globally, particularly in developing countries in Southeast Asia and sub-Saharan Africa (SSA), where chronic hepatitis B virus (HBV) dominates as a major aetiological factor.
Methods: We conducted a retrospective cohort study to quantify the metastatic profile of HCC in a South African patient population managed at a tertiary centre. Demographic, clinical and treatment data were extracted from an institutional registry.
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial.
ESMO Open
January 2025
Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, (Milan), Italy. Electronic address:
Background: The treatment of advanced hepatocellular carcinoma (HCC) with atezolizumab and bevacizumab led to significant improvements in overall survival (OS), progression-free survival (PFS), and response rate compared with sorafenib in the phase III IMbrave150 trial. The etiology of background liver disease can differ between Eastern and Western populations, leading to a potentially different impact of systemic therapies; therefore the unequal representation must be considered in the IMbrave150 trial. To provide further data on the safety and effectiveness of atezolizumab and bevacizumab, the phase IIIb AMETHISTA (Atezolizumab plus bevacizumab in METastatic HCC Italian Safety TriAl) ran in a Western (Italian) population of patients with advanced HCC.
View Article and Find Full Text PDFProgrammed cell death (PCD) is a significant factor in the progression of hepatocellular carcinoma (HCC) and might serve as a crucial marker for predicting HCC prognosis and therapy response. However, the classification of HCC based on diverse PCD patterns requires further investigation. This study identified a novel molecular classification named PCD subtype (C1, C2, and C3) based on the genes associated with 19 PCD patterns, distinguished by clinical, biological functional pathways, mutations, immune characteristics, and drug sensitivity.
View Article and Find Full Text PDFA split-type near-infrared photoelectrochemical and colorimetric dual-mode biosensor for the high-performance determination of HepG2 cells.
Talanta
January 2025
School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China. Electronic address:
Hepatocellular carcinoma (HCC) stands as a grave illness characterized by elevated death rates. Early identification plays a vital role in improving patient survival. Herein, a novel split-type dual-mode biosensor featuring with near-infrared photoelectronchemical (PEC) and colorimetric sensing characteristics was developed for the high-performance detection of HepG2 cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!